ArticleVeterinary research communications2026
Characterization and mechanistic regulation of the Bovine inflammasome.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Inflammasomes, intracellular multi-protein complexes, sense cytosolic danger signals, leading to the initiation and amplification of inflammation via the maturation of the pro-inflammatory cytokine IL-1β and the induction of inflammatory cell death. Different inflammasomes recognize distinct danger signals and pathogens, which is crucial for both physiological immunity and therapeutic targeting. Although inflammasomes have been studied extensively in humans and mice, research in cattle remains limited. In this study, bovine peripheral blood monocytes (PBMC) were treated with various stimuli and inhibitors of several inflammasomes, and mature IL-1β secretion was measured as a readout of inflammasome activation. Bovine PBMC responded to all the test stimuli in a dose-dependent manner, promoting IL-1β secretion. Inhibitor assays showed that bovine NLRP3 and non-canonical inflammasome activation were similar to those in mice, whereas flagellin- and dsDNA-mediated activation was uniquely inhibited by the potassium efflux inhibitor glibenclamide and the NLRP3-specific inhibitor MCC950. In contrast to murine responses, Staphylococcus aureus induced inflammasome activation in bovine PBMC was entirely dependent on NLRP3. Although bovine PBMC responded normally to a broad range of known inflammasome stimuli, their activation mechanisms differ from those of mice, relying predominantly on NLRP3, which was consistently inhibited by MCC950. These findings offer novel insights into the bovine inflammasome biology and may contribute to the understanding of inflammasome-related diseases in cattle.
Indexed as
Identifiers
42018043What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.